Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients

Authors Ravinder Dhillon, Simona Rossi, Steven K Herrine

Published 8 August 2008 Volume 2008:4(4) Pages 789—796


Ravinder Dhillon, Simona Rossi, Steven K Herrine

Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USA

Abstract: Coinfection with hepatitis C virus (HCV) and HIV is an increasingly recognized clinical dilemma, particularly since the advent of highly active antiretroviral therapy. Several studies of this population have demonstrated both more rapid progression of liver disease and poorer overall prognosis compared to HCV monoinfected patients. Consensus guidelines, based primarily on the results of 4 major randomized trials, recommend treatment with peginterferon and ribavirin for 48 weeks in coinfected patients. However, this current standard of care is associated with lower response rates to therapy than those seen in monoinfected patients. Important predictors of response include HCV genotype, pretreatment HCV RNA level, and presence of rapid virologic response (RVR) and early virologic response (EVR). Use of weight-based ribavirin dosing appears to be safe and enhances the likelihood of sustained virologic response (SVR). Adverse effects most commonly encountered are anemia and weight loss. Mitochondrial toxicity can occur in the setting of concomitant nucleoside reverse transcriptase inhibitor use, especially didanosine, abacavir, and zidovudine, and these should be discontinued before initiation of ribavirin therapy. Discontinuation of therapy should be considered in patients failing to demonstrate EVR, though ongoing trials are investigating a potential role for maintenance therapy in these patients. Peginterferon combined with weight-based ribavirin is appropriate and safe for treatment of HCV in HIV – HCV coinfected patients. This review summarizes the data supporting these recommendations.

Keywords: hepatitis C, human immunodeficiency virus, peginterferon, ribavirin

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Patient risk factors for developing a drug-related problem in a cardiology ward

Urbina O, Ferrández O, Luque S, Grau S, Mojal S, Pellicer R, Riu M, Salas E, Comin-Colet J

Therapeutics and Clinical Risk Management 2015, 11:9-15

Published Date: 17 December 2014

Knowledge about COPD among users of primary health care services

Queiroz MC, Moreira MA, Jardim JR, Barbosa MA, Minamisava R, Gondim HD, Velasco FC, Penhavel MV

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1-6

Published Date: 17 December 2014

Worldwide increase in diabetes: implications for tuberculosis control

Fisher-Hoch SP

Research and Reports in Tropical Medicine 2014, 5:35-44

Published Date: 3 July 2014

Purple urine bag syndrome in nursing homes: Ten elderly case reports and a literature review

Chi-Hung Lin, Hsien-Te Huang, Chia-Chang Chien, Dong-Sheng Tzeng, For-Wey Lung

Clinical Interventions in Aging 2008, 3:729-734

Published Date: 5 December 2008

Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients

Dimitrios Chantzichristos, Andréasson Björn, Johansson Peter

Therapeutics and Clinical Risk Management 2008, 4:1371-1374

Published Date: 5 December 2008

Patient identified needs for chronic obstructive pulmonary disease versus billed services for care received

Jill Heins-Nesvold, Angeline Carlson, Leslie King-Schultz, Kenneth E Joslyn

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:415-421

Published Date: 12 September 2008

Pulmonary hypertension and chronic cor pulmonale in COPD

Adil Shujaat, Ruth Minkin, Edward Eden

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:273-282

Published Date: 15 October 2007

Physiological associations of computerized tomography lung density: a factor analysis

Suzanne Marsh, Sarah Aldington, Mathew V Williams, Michael Nowitz, Andrew Kingzett-Taylor, et al

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:181-187

Published Date: 15 June 2006